- Home
- ANAB vs GFR Comparison
ANAB vs GFR Comparison
Compare ANAB & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GFR
- Stock Information
- Founded
- ANAB 2005
- GFR 2018
- Country
- ANAB United States
- GFR Canada
- Employees
- ANAB N/A
- GFR N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GFR
- Sector
- ANAB Health Care
- GFR
- Exchange
- ANAB Nasdaq
- GFR Nasdaq
- Market Cap
- ANAB 600.4M
- GFR 489.7M
- IPO Year
- ANAB 2017
- GFR N/A
- Fundamental
- Price
- ANAB $22.27
- GFR $7.78
- Analyst Decision
- ANAB Buy
- GFR Buy
- Analyst Count
- ANAB 11
- GFR 1
- Target Price
- ANAB $54.64
- GFR $10.50
- AVG Volume (30 Days)
- ANAB 623.5K
- GFR 117.0K
- Earning Date
- ANAB 11-05-2024
- GFR 11-14-2024
- Dividend Yield
- ANAB N/A
- GFR N/A
- EPS Growth
- ANAB N/A
- GFR N/A
- EPS
- ANAB N/A
- GFR 0.40
- Revenue
- ANAB $57,172,000.00
- GFR $551,353,492.00
- Revenue This Year
- ANAB $207.49
- GFR $35.03
- Revenue Next Year
- ANAB N/A
- GFR $37.50
- P/E Ratio
- ANAB N/A
- GFR $19.30
- Revenue Growth
- ANAB 282.17
- GFR 7.93
- 52 Week Low
- ANAB $13.36
- GFR $4.68
- 52 Week High
- ANAB $41.31
- GFR $8.16
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- GFR 53.13
- Support Level
- ANAB $18.03
- GFR $6.80
- Resistance Level
- ANAB $22.94
- GFR $7.27
- Average True Range (ATR)
- ANAB 1.37
- GFR 0.29
- MACD
- ANAB 0.45
- GFR -0.02
- Stochastic Oscillator
- ANAB 86.18
- GFR 50.43
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.